The Minimal Residual Disease market report covers emerging drugs, current treatment practices, market share of the individual therapies, current and forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Minimal Residual Disease: An Overview
According to the National Cancer Institute (NCI) the term Minimal Residual Disease (MRD) describes a very small number of cancer cells that remain in the body during or after treatment. It is mostly used for blood cancers such as lymphoma and leukemias. After treating cancer, any remaining cancer cells in the body can become active and start to multiply, causing a relapse of the disease. Detecting MRD may indicate that the treatment was not completely effective or that the treatment was incomplete. It happens so because not all of the cancer cells responded to the therapy, or because the cancer cells became resistant to the medications used.
According to the Leukemia and Lymphoma Society (LLS), a Minimal Residual Disease positive test result means that the disease was still detected after treatment. An MRD negative result means that no disease was detected after treatment.
Minimal Residual Disease Market Key Facts
As per the study by Pigneux et al. 2018, large prospective multicenter studies have found that 33–47% of patients have MRD after induction therapy. These studies have shown a strong association between the presence of MRD after front-line therapy and poor long-term outcomes, including an increased risk of relapse and shorter relapse-free, disease-free, and overall survival.
The treatment scenario of Minimal Residual Disease includes intensive conventional therapies with more drugs or different combinations along with marrow transplants.
As per the study by Bene and Kaeda 2009, in a study on patients with Chronic Lymphocytic Leukemia (CLL), the results showed that 21% of the patients assessed had undetectable MRD, with a median time of progression of 44 months compared with 27 months with detectable CLL cells.
The Minimal Residual Disease (MRD) Market Size is anticipated to increase during the study period owing to the increasing prevalent population of Minimal Residual Disease (MRD) patients in the 7MM, along with promising assets. Extensive research and development activities of pharmaceutical companies will also fuel market growth.
The market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Minimal Residual Disease market size by analyzing the impact of current and emerging therapies in the market. It also provides a detailed assessment of the market drivers & barriers, unmet needs, and emerging technologies.
The report gives a thorough detail of the Minimal Residual Disease market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action (MoA), competition with other therapies, brand value, their impact on the market and view of the key opinion leaders.
Minimal Residual Disease Epidemiology
The epidemiology section covers insights about the historical and current Minimal Residual Disease patient pool and forecasted trends for every seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Minimal Residual Disease Epidemiology Segmentation
Total Prevalent cases of Minimal Residual Disease
Severity-specific cases of Minimal Residual Disease
Cases of Minimal Residual Disease by Cause
Diagnosed Cases of Minimal Residual Disease
Minimal Residual Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Minimal Residual Disease market or expected to get launched in the market during the study period. The analysis covers Minimal Residual Disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report also covers the Minimal Residual Disease Pipeline Development Activities and provides valuable insights about different therapeutic candidates in Phase II, and Phase III stages and the key companies in the market involved in developing targeted therapeutics. It also analyses the recent Development such as collaborations, acquisitions, and mergers, licensing patent details, and other information for emerging therapies.
Minimal Residual Disease Therapeutics Analysis
The available therapeutics treatment options in Minimal Residual Disease (MRD) Landscape aim at using conventional treatment with more drugs or different combinations of drugs.
To eradicate relapses and provide better therapeutic options in Minimal Residual Disease many trials are going on. Few drugs in the late phase of development are expected to enter the market by 2030. All of these therapies target different mechanisms and are expected to provide better treatment for Minimal Residual Disease patients.
Get the PDF Sample of the Report:- https://www.delveinsight.com/sample-request/minimal-residual-disease-market
Some of the key companies in the Minimal Residual Disease Market Include:
Minimal Residual Disease Therapies covered in the report includes
Daratumumab + Lenalidomide
Midostaurin + Combination
And many more.
Get More Detailed Insights into the Emerging Therapies & Key Companies:- https://www.delveinsight.com/sample-request/minimal-residual-disease-market
Table of Content
1. Key Insights
2. Executive Summary
3. Minimal Residual Disease Competitive Intelligence Analysis
4. Minimal Residual Disease Market Overview at a Glance
5. Minimal Residual Disease Disease Background and Overview
6. Minimal Residual Disease Patient Journey
7. Minimal Residual Disease Epidemiology and Patient Population
8. Minimal Residual Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Minimal Residual Disease Unmet Needs
10. Key Endpoints of Minimal Residual Disease Treatment
11. Minimal Residual Disease Marketed Products
12. Minimal Residual Disease Emerging Therapies
13. Minimal Residual Disease Seven Major Market Analysis
14. Attribute Analysis
15. Minimal Residual Disease Market Outlook (7 major markets)
16. Minimal Residual Disease Access and Reimbursement Overview
17. KOL Views on the Minimal Residual Disease Market.
18. Minimal Residual Disease Market Drivers
19. Minimal Residual Disease Market Barriers
21. DelveInsight Capabilities
*The table of contents is not exhaustive; the final content may vary.
Request Sample Report here:- https://www.delveinsight.com/sample-request/minimal-residual-disease-market
Other Trending Healthcare Reports By DelveInsight
DelveInsight’s “Bacterial (Pyogenic) Meningitis Market” research report delivers an in-depth understanding of the historical and forecasted epidemiology, Bacterial (Pyogenic) Meningitis market size, share, trends, emerging therapies, and key companies actively operating in the market.
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States